Fusion Pharmaceuticals Inc (NASDAQ:FUSN)’s traded shares stood at 3.41 million during the latest session, with the company’s beta value hitting -0.69. At the last check today, the stock’s price was $21.41, to imply a decrease of -0.02% or $0.0 in intraday trading. The FUSN share’s 52-week high remains $21.58, putting it -0.79% down since that peak but still an impressive 89.21% since price per share fell to its 52-week low of $2.31. The company has a valuation of $1.82B, with an average of 1.86 million shares over the past 3 months.
Fusion Pharmaceuticals Inc (NASDAQ:FUSN) trade information
After registering a -0.02% downside in the latest session, Fusion Pharmaceuticals Inc (FUSN) has traded red over the past five days. The stock hit a weekly high of 21.56, dropping -0.02% in its intraday price action. The 5-day price performance for the stock is -0.53%, and -0.12% over 30 days. With these gigs, the year-to-date price performance is 122.74%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Fusion Pharmaceuticals Inc (FUSN) estimates and forecasts
Looking at statistics comparing Fusion Pharmaceuticals Inc share performance against respective industry, we note that the company has underperformed competitors. Fusion Pharmaceuticals Inc (FUSN) shares are 351.58% up over the last 6 months, with its year-to-date growth rate lower than industry average at 0.69% against 13.60%. The rating firms project that company’s revenue will shrink -81.10% compared to the previous financial year.
Revenue forecast for the current quarter as set by 6 analysts is 160k. Meanwhile, for the current quarter, a total of 6 analyst(s) estimate revenue growth to 150k.Earnings reports from the last fiscal year show that sales brought in 80k and 100k respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 100.00% before jumping 50.00% in the following quarter.
FUSN Dividends
Fusion Pharmaceuticals Inc has its next earnings report out in June. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Fusion Pharmaceuticals Inc has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
